News & Events

PHMR Limited joins Putnam Associates, part of Ashfield Advisory

January 26, 2021
|
Industry News, Firm News

January 26, 2021 Boston, MA: Putnam Associates, part of Ashfield Advisory, announces that PHMR Limited, a global consulting firm specializing in market access and health economics outcomes research (HEOR), will join Putnam’s Value, Pricing and Access practice area.

PHMR specializes in health economics, real world evidence, patient reported outcomes, health technology assessments and other HEOR activities which support market access for global life sciences clients.

Putnam Associates specializes in strategy consulting exclusively for the life sciences. The addition of PHMR will strengthen Putnam’s Global Value, Pricing and Access practice area by adding complementary HEOR and research science expertise, as well as expanding the company’s depth in Europe and Japan.

Remco op den Kelder, CEO of Putnam added:

“Since joining Ashfield Advisory, we’ve been seeking opportunities to further expand our existing global footprint. PHMR clearly meets that objective in an area that is of great strategic importance to Putnam and our clients. We were thoroughly impressed from our first interaction with the PHMR team and we could not be more excited to see the collective value we will bring to our clients.”

Eric Auger, Putnam’s Global Value, Pricing and Access Practice Area Lead, added:

“The scientific and technical expertise that PHMR brings in HEOR and HTA will be a great complement to the strategic pricing and market access expertise of the Putnam Value, Pricing and Access team. We’re very excited to bring this broader value offering to our clients.”

Founded in 2008, PHMR is headquartered in London with offices in Newcastle, UK and Westport, Ireland. PHMR employs a multidisciplinary, highly qualified team of 40 health economists and research scientists.

Commenting on the acquisition, Mark Ratcliffe, Founder of PHMR, said:

“This acquisition brings great opportunities to both our current and future clients, as we’ll be able to offer the same exceptional service, with the added value of being connected to the Ashfield Advisory ecosystem, as and when our clients need additional support.

“I am extremely proud of the team at PHMR and what we have achieved together. I am very grateful for all their hard work and I am looking forward to seeing what we can accomplish together as part of the Putnam Associates team.”

To learn more about PHMR, visit www.phmr.com.

 

About Putnam Associates

Founded in 1988, with offices in Boston, San Francisco, New York and London, Putnam Associates serves the global life sciences industry providing world class strategic advice based on sophisticated, robust analytics. The company provides customized, actionable recommendations that draw on robust problem framing, cutting-edge methodologies, deep therapeutic area knowledge, extensive global networks of health care stakeholders, and expert synthesis across scientific, clinical, and business disciplines. Putnam’s work is dedicated to maximizing the value of the pharmaceutical, biotechnology, diagnostic and device products by serving clients who market many of the world’s best-known biopharmaceuticals.

About Ashfield Advisory

Ashfield Advisory, part of UDG Healthcare plc, is an ecosystem of connected advisory and consulting businesses including Vynamic, Putnam Associates (including newly acquired PHMR), STEM Healthcare and SmartAnalyst. All four businesses have specific areas of expertise and are focused on market access and shaping the healthcare industry by hiring top talent, building deep industry expertise, cultivating a boutique approach to client partnerships, and capitalizing on the team’s expansive research and data insights.

Under the Ashfield umbrella, Ashfield Advisory sits alongside Ashfield Engage and Ashfield Health.

For more information, go to www.ashfieldadvisory.com

Contact Information

For more information please contact:

Kam Olaogun, Putnam Associates Marketing Manager | kam.olaogun@putassoc.com | 617.456.5200

Strategy for the Life Sciences